Article

Vaccine hesitancy, reactogenicity and immunogenicity of BNT162b2 and CoronaVac in pediatric patients with neuromuscular diseases

2022-11-30

Abstract excerpt

<h4>Introduction</h4> COVID-19 causes global health and psychosocial devastation, particularly to high-risk patients such as those with neuromuscular diseases (NMDs). The mRNA-based BNT162b2 and inactivated whole-virus CoronaVac are two novel COVID-19 vaccines widely used across the world that confer immune protection to healthy individuals. However, hesitancy towards COVID-19 vaccination was common for patients w...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bdb49376-3384-5d1e-ba7e-fbf5d2038dd9
DOI: 10.1101/2022.11.29.22282857

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Vaccine hesitancy, reactogenicity and immunogenicity of BNT162b2 and CoronaVac in pediatric patients with neuromuscular diseasesDOI 10.1101/2022.11.29.22282857Read

COVID-19 Vaccine Hesitancy Among Parents of Children Under Five Years in the United StatesSemantic proximity Read

COVID-19 vaccine hesitancy among individuals with cancer, autoimmune diseases, and other serious comorbid conditionsSemantic proximity Read

Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 TrialSemantic proximity Read

Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years (CoVacU5) – an Investigator-Initiated Retrospective Cohort StudySemantic proximity Read

Effectiveness of BNT162b2 COVID-19 Vaccination in Children Aged 5–17 Years in the United StatesSemantic proximity Read

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, EnglandSemantic proximity Read

Immunologic response, Efficacy, and Safety of Vaccines Against COVID-19 Infection in Children and Adolescents Aged 2 – 21 years old: A Systematic ReviewSemantic proximity Read

Vaccination against SARS-CoV-2 in UK school-aged children and young people decreases infection rates and reduces COVID-19 symptomsSemantic proximity Read

Real-world Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and AdolescentsSemantic proximity Read

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron VariantSemantic proximity Read

Vaccine hesitancy among legal guardians of children with chronic neurological disorders: a cross-sectional study in Saudi ArabiaSemantic proximity Read

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccineSemantic proximity Read